Cameron Black

EVP, Discovery

Cameron joined Repare Therapeutics in mid-2016 to lead the drug discovery efforts on newly identified synthetic lethal targets. Prior to this, he spent 18 years at Merck Frosst during which time he was responsible for the identification of seven drug candidates. He led both the discovery and early clinical development of the cathepsin K inhibitor odanacatib, a once-weekly treatment for osteoporosis.

+ Show More

Steve Forte

EVP, Chief Financial Officer

Steve is a senior finance leader with broad experience managing complex, large-scale finance environments. He was most recently CFO of Clementia Pharmaceuticals (NASDAQ: CMTA), which was sold earlier this year to Ipsen S.A. in a transaction valued at US$1.3 billion.

+ Show More

Maria Koehler

EVP & Chief Medical Officer

Maria joined Repare Therapeutics in May 2019 as the Executive Vice President, Chief Medical Officer. She is a hematologist/oncologist with 20 years in pharmaceutical and biotechnology companies and has experience in both early drug development and bringing new drugs to global markets, having developed strategies for all stages of cancer drug development and medical affairs.

+ Show More

Lloyd M. Segal

President & CEO

In addition to his role as Repare’s President & CEO, Lloyd is an Entrepreneur-in-residence at Versant Ventures. From 2010-2016 he was a Managing Partner at Persistence Capital Partners, a leading healthcare private equity investor. Lloyd held CEO roles at Caprion Pharmaceticals, Advanced Bioconcept and Thallion Pharmaceuticals, and has served as a director of several public and private corporations in the U.S. and Canada.

+ Show More

Kim Seth

EVP, Head of Business & Corporate Development

Kim is Executive Vice President, Head of Business & Corporate Development at Repare. Prior to joining Repare, he was Chief Business Officer and Chief Operating Officer at Resilience Therapeutics and CBO/SVP of Corporate Development & Strategy at Epirus Biopharmaceuticals.

+ Show More

Theresa Zhang

VP, Translational Science

Theresa joined Repare Therapeutics in January 2018 as VP of Translational Science.
Prior to this, she spent 13 years at Merck. She led a team of oncology translational scientists to identify patient stratification biomarkers for early stage compounds and oversaw the development of fit-for-purpose CLIA assays for use in cancer clinical trials.

+ Show More

Michael Zinda

EVP, Chief Scientific Officer

Michael is the Executive Vice President, Chief Scientifc Officer at Repare Therapeutics. Prior to joining Repare, he led the oncology bioscience organization at AstraZeneca R&D Boston. In this role he served on the global science leadership team, oncology research board and the Acerta research and early development teams accountable for strategy, key collaborations/partnerships and delivery of an innovative portfolio of patient centric drug discovery programs.

+ Show More